Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
9
mi
from 98109
Seattle, WA
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
9
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)
Status: Enrolling
Updated:  12/31/1969
Froedtert and the Medical College of Wisconsin
1681
mi
from 98109
Milwaukee, WI
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)
Status: Enrolling
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
1681
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital
1029
mi
from 98109
Aurora, CO
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital
1029
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status
Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status by Biopsy and mRNA Profiles (TIMELY Study)
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Medical College/NewYork-Presbyterian Hospital
2401
mi
from 98109
New York, NY
Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status
Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status by Biopsy and mRNA Profiles (TIMELY Study)
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medical College/NewYork-Presbyterian Hospital
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Wisconsin
1681
mi
from 98109
Milwaukee, WI
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Wisconsin
1681
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial
Status: Enrolling
Updated:  12/31/1969
Froedtert and the Medical College of Wisconsin
1681
mi
from 98109
Milwaukee, WI
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial
Status: Enrolling
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
1681
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
9
mi
from 98109
Seattle, WA
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
9
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2679
mi
from 98109
Honolulu, HI
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2679
mi
from 98109
Honolulu, HI
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1939
mi
from 98109
Louisville, KY
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1939
mi
from 98109
Louisville, KY
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1183
mi
from 98109
Albuquerque, NM
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1183
mi
from 98109
Albuquerque, NM
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2371
mi
from 98109
Philadelphia, PA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1769
mi
from 98109
Austin, TX
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1769
mi
from 98109
Austin, TX
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1058
mi
from 98109
San Diego, CA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1058
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
680
mi
from 98109
San Francisco, CA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1022
mi
from 98109
Denver, CO
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1022
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1004
mi
from 98109
Louisville, CO
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1004
mi
from 98109
Louisville, CO
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2515
mi
from 98109
Clearwater, FL
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2515
mi
from 98109
Clearwater, FL
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2730
mi
from 98109
Miami, FL
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2690
mi
from 98109
West Palm Beach, FL
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2690
mi
from 98109
West Palm Beach, FL
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2296
mi
from 98109
Augusta, GA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2296
mi
from 98109
Augusta, GA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1557
mi
from 98109
Iowa City, IA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1557
mi
from 98109
Iowa City, IA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1474
mi
from 98109
Arkansas City, KA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1474
mi
from 98109
Arkansas City, KA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1420
mi
from 98109
Newton, KA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1420
mi
from 98109
Newton, KA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1440
mi
from 98109
Wichita, KA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1440
mi
from 98109
Wichita, KA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1968
mi
from 98109
Bardstown, KY
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1968
mi
from 98109
Bardstown, KY
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1392
mi
from 98109
Minneapolis, MN
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1392
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1365
mi
from 98109
Omaha, NE
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1365
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2393
mi
from 98109
Lebanon, NH
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2393
mi
from 98109
Lebanon, NH
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2377
mi
from 98109
Morristown, NJ
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2377
mi
from 98109
Morristown, NJ
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2400
mi
from 98109
New York, NY
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2374
mi
from 98109
Poughkeepsie, NY
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2374
mi
from 98109
Poughkeepsie, NY
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2337
mi
from 98109
Chapel Hill, NC
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2337
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2462
mi
from 98109
New Bern, NC
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2462
mi
from 98109
New Bern, NC
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2024
mi
from 98109
Cleveland, OH
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2024
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1561
mi
from 98109
Tulsa, OK
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1561
mi
from 98109
Tulsa, OK
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
145
mi
from 98109
Portland, OR
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
145
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2129
mi
from 98109
Carnegie, PA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2129
mi
from 98109
Carnegie, PA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2075
mi
from 98109
Erie, PA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2075
mi
from 98109
Erie, PA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2137
mi
from 98109
Pleasant Hills, PA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2137
mi
from 98109
Pleasant Hills, PA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1892
mi
from 98109
Houston, TX
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
1876
mi
from 98109
Webster, TX
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
1876
mi
from 98109
Webster, TX
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2285
mi
from 98109
Charlottesville, VA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2285
mi
from 98109
Charlottesville, VA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
226
mi
from 98109
Spokane, WA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
226
mi
from 98109
Spokane, WA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
95
mi
from 98109
Wenatchee, WA
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
95
mi
from 98109
Wenatchee, WA
Click here to add this to my saved trials
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
562
mi
from 98109
Edmonton,
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
562
mi
from 98109
Edmonton,
Click here to add this to my saved trials
Effect of Raltegravir on Endothelial Function in HIV-Infected Patients
A Randomized, Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Effect of Raltegravir on Endothelial Function in HIV-Infected Patients
A Randomized, Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension
Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension
Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
682
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia
Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in the Neutropenic Patient
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
2274
mi
from 98109
Winston-Salem, NC
Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia
Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in the Neutropenic Patient
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
2274
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization
Prevalence of Methicillin-resistant Staphylococcus Aureus (MRSA) in a Medical Center and Efficacy of Altabax in Clearing MRSA Nasal Colonization
Status: Enrolling
Updated:  12/31/1969
Tulane University School of Medicine
2099
mi
from 98109
New Orleans, LA
Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization
Prevalence of Methicillin-resistant Staphylococcus Aureus (MRSA) in a Medical Center and Efficacy of Altabax in Clearing MRSA Nasal Colonization
Status: Enrolling
Updated: 12/31/1969
Tulane University School of Medicine
2099
mi
from 98109
New Orleans, LA
Click here to add this to my saved trials
Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization
Prevalence of Methicillin-resistant Staphylococcus Aureus (MRSA) in a Medical Center and Efficacy of Altabax in Clearing MRSA Nasal Colonization
Status: Enrolling
Updated:  12/31/1969
Ochsner Health System
2095
mi
from 98109
New Orleans, LA
Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization
Prevalence of Methicillin-resistant Staphylococcus Aureus (MRSA) in a Medical Center and Efficacy of Altabax in Clearing MRSA Nasal Colonization
Status: Enrolling
Updated: 12/31/1969
Ochsner Health System
2095
mi
from 98109
New Orleans, LA
Click here to add this to my saved trials